Literature DB >> 22264484

Synthesis and antihypertensive activity of pyrimidin-4(3H)-one derivatives as losartan analogue for new angiotensin II receptor type 1 (AT1) antagonists.

Tae Woo Kim1, Byoung Wook Yoo, Joon Kwang Lee, Ji Han Kim, Kyung-Tae Lee, Yong Ha Chi, Jae Yeol Lee.   

Abstract

The discovery, in vitro and in vivo studies of the highly potent AT(1) antagonist 12a (BR-A-657, Fimasartan) antagonists are presented. A series of pyrimidin-4(3H)-one derivatives as losartan analogue were synthesized and evaluated for a novel class of AT(1) receptor antagonists. Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC(50)=0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED(50) of 0.018 mg/kg. Moreover, in vivo evaluation in furosemide-treated rat and conscious renal hypertensive rat models and the pharmacokinetic study showed that 12a is a highly potent and orally active AT(1) selective antagonist having stronger in vivo potency than losartan.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22264484     DOI: 10.1016/j.bmcl.2011.12.116

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  Fimasartan: A New Angiotensin Receptor Blocker.

Authors:  Hae-Young Lee; Byung-Hee Oh
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

2.  Population Pharmacokinetic Modeling of the Enterohepatic Recirculation of Fimasartan in Rats, Dogs, and Humans.

Authors:  Tae Hwan Kim; Soyoung Shin; Cornelia B Landersdorfer; Yong Ha Chi; Soo Heui Paik; Jayhyuk Myung; Rajbharan Yadav; Stefan Horkovics-Kovats; Jürgen B Bulitta; Beom Soo Shin
Journal:  AAPS J       Date:  2015-05-20       Impact factor: 4.009

3.  Chemical Synthesis Enables Structural Reengineering of Aglaroxin C Leading to Inhibition Bias for Hepatitis C Viral Infection.

Authors:  Wenhan Zhang; Shufeng Liu; Rayelle I Maiga; Jerry Pelletier; Lauren E Brown; Tony T Wang; John A Porco
Journal:  J Am Chem Soc       Date:  2019-01-11       Impact factor: 15.419

4.  Efficacy of fimasartan/hydrochlorothiazide combination in hypertensive patients inadequately controlled by fimasartan monotherapy.

Authors:  Moo-Yong Rhee; Sang Hong Baek; Weon Kim; Chang Gyu Park; Seung Woo Park; Byung-Hee Oh; Sang-Hyun Kim; Jae-Joong Kim; Joon-Han Shin; Byung-Su Yoo; Se-Joong Rim; Jong-Won Ha; Joon Hyung Doh; Youngkeun Ahn; Jei Keon Chae; Jeong Bae Park; Soon-Kil Kim; Cheol Ho Kim
Journal:  Drug Des Devel Ther       Date:  2015-06-02       Impact factor: 4.162

5.  FimAsartaN proTeinuriA SusTaIned reduCtion in comparison with losartan in diabetic chronic kidney disease (FANTASTIC): study protocol for randomized controlled trial.

Authors:  Jang-Young Kim; Jung-Woo Son; Sungha Park; Tea-Hyun Yoo; Yong-Jin Kim; Dong-Ryeol Ryu; Ho Jun Chin
Journal:  Trials       Date:  2017-12-29       Impact factor: 2.279

6.  Fimasartan attenuates renal ischemia-reperfusion injury by modulating inflammation-related apoptosis.

Authors:  Jang-Hee Cho; Soon-Youn Choi; Hye-Myung Ryu; Eun-Joo Oh; Ju-Min Yook; Ji-Sun Ahn; Hee-Yeon Jung; Ji-Young Choi; Sun-Hee Park; Chan-Duck Kim; Yong-Lim Kim
Journal:  Korean J Physiol Pharmacol       Date:  2018-10-25       Impact factor: 2.016

7.  Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway.

Authors:  Inho Kim; Chan Soon Park; Hae Young Lee
Journal:  Korean Circ J       Date:  2019-03-05       Impact factor: 3.243

8.  Fimasartan reduces neointimal formation and inflammation after carotid arterial injury in apolipoprotein E knockout mice.

Authors:  Jong-Ho Kim; I-Rang Lim; Hyung Joon Joo; Chi-Yeon Park; Seung-Cheol Choi; Han Saem Jeong; Soon Jun Hong
Journal:  Mol Med       Date:  2019-07-15       Impact factor: 6.354

9.  Safety and efficacy of fimasartan in patients with arterial hypertension (Safe-KanArb study): an open-label observational study.

Authors:  Jeong Bae Park; Ki-Chul Sung; Seok-Min Kang; Eun Joo Cho
Journal:  Am J Cardiovasc Drugs       Date:  2013-02       Impact factor: 3.571

10.  Effect of Long-Term Treatment with Fimasartan on Transient Focal Ischemia in Rat Brain.

Authors:  Chi Kyung Kim; Xiu-Li Yang; Young-Ju Kim; In-Young Choi; Han-Gil Jeong; Hong-Kyun Park; Dohoung Kim; Tae Jung Kim; Hyunduk Jang; Sang-Bae Ko; Byung-Woo Yoon
Journal:  Biomed Res Int       Date:  2015-09-13       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.